title: Reply to F. Valcamonico et al.
authors.affiliation: Massachusetts General Hospital Cancer Center, Boston, MA smith.matthew@mgh.harvard.edu.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
authors.affiliation: Duke University Medical Center, Durham, NC.
authors.forename: Susan
authors.initials: S
authors.lastname: Halabi
authors.affiliation: University of California, San Francisco, San Francisco, CA.
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Small
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles